Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either Surgery or Chemotherapy.

Next Previous
X
Search
Trial Profile

Phase II, Open, Single Group, Multicentre Study to Evaluate the Efficacy and Safety of Lanreotide Autogel Administered Every 4 Weeks by Deep Subcutaneous Injection in the Tumour's Growth Stabilization of Patients With Progressive Neuroendocrine Tumours Who Are Not Eligible to be Treated With Either Surgery or Chemotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Carcinoma; Neuroendocrine tumours
  • Focus Biomarker; Therapeutic Use
  • Sponsors Ipsen

    • Most Recent Events

    • 21 Jan 2017 Results of pooled analysis (n=378) of 5 clinical trials (NCT00353496, NCT00842348, NCT00774930, NCT00681187 and NCT00326469) presented at the 2017 Gastrointestinal Cancers Symposium
    • 30 Nov 2010 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.
    • 30 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top